AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24226381 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Group I)
Number of subjects: 308
Study 24226381 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 308
Study 21113820 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring measures
Number of subjects: 0
Study 21113820 — intervention group
Group type: COMPARATOR
Intervention: Self-assessment
Number of subjects: 0
Study 19526613 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte-depleted (LD) RBC transfusion
Number of subjects: 512
Study 19526613 — intervention group
Group type: COMPARATOR
Intervention: Non-leucocyte-depleted (non-LD) RBC transfusion
Number of subjects: 512
Study 17275889 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin and pelvic radiation (GOG 120)
Number of subjects: 335
Study 17275889 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin and pelvic radiation (GOG 165)
Number of subjects: 335
Study 17275889 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged radiation (GOG 165)
Number of subjects: 335
Study 15942776 — intervention group
Group type: EXPERIMENTAL
Intervention: Flatfoot deformity stage 2 patients
Number of subjects: 150
Study 15942776 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical strategies including stage 2 soft tissue reconstruction and hindfoot osteotomies combined with hindfoot arthrodeses (subtalar fusion)
Number of subjects: 150
Study 15942776 — intervention group
Group type: COMPARATOR
Intervention: Patients with no hindfoot malalignment
Number of subjects: 150
Study 11831543 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin immediate-release (IR) 40 mg tablets following a standard breakfast
Number of subjects: 9
Study 11831543 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin extended-release (ER) 40 mg tablets following a standard breakfast
Number of subjects: 9
Study 11831543 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin extended-release (ER) 40 mg tablets under fasting conditions
Number of subjects: 9
Study 11831543 — intervention group
Group type: COMPARATOR
Intervention: lovastatin extended-release (ER) tablets with breakfast
Number of subjects: 9
Study 10037132 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered blood transfusion
Number of subjects: 52
Study 10037132 — intervention group
Group type: COMPARATOR
Intervention: Nonfiltered blood transfusion
Number of subjects: 52
Study 7728285 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (1 g/d)
Number of subjects: 138
Study 7728285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 2140332 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tetracycline applied twice daily for 16 weeks
Number of subjects: 85
Study 2140332 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied twice daily for 16 weeks
Number of subjects: 85
Study 6101956 — intervention group
Group type: COMPARATOR
Intervention: Clorazepate dipotassium 5 mg
Number of subjects: 17
Study 6101956 — intervention group
Group type: COMPARATOR
Intervention: Clorazepate dipotassium 7.5 mg
Number of subjects: 17
Study 6101956 — intervention group
Group type: COMPARATOR
Intervention: Clorazepate dipotassium 15 mg
Number of subjects: 17
Study 6101956 — intervention group
Group type: COMPARATOR
Intervention: Clorazepate dipotassium 7.5 mg/day for 14 days
Number of subjects: 17
Study 6101956 — intervention group
Group type: COMPARATOR
Intervention: Clorazepate dipotassium 15 mg/day for 14 days
Number of subjects: 17
Study 6101956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 29889653 — intervention group
Group type: EXPERIMENTAL
Intervention: Barefoot running for 20 minutes
Number of subjects: 26
Study 29889653 — intervention group
Group type: EXPERIMENTAL
Intervention: Shod running for 20 minutes
Number of subjects: 26
Study 28100321 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol treatment
Number of subjects: 102
Study 28100321 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 102
Study 26015434 — intervention group
Group type: EXPERIMENTAL
Intervention: euinsulinemia-hyperglycemia
Number of subjects: 22
Study 26015434 — intervention group
Group type: EXPERIMENTAL
Intervention: hyperinsulinemia-hyperglycemia
Number of subjects: 22
Study 26015434 — intervention group
Group type: COMPARATOR
Intervention: euinsulinemia-euglycemia
Number of subjects: 22
Study 26015434 — intervention group
Group type: COMPARATOR
Intervention: hyperinsulinemia-euglycemia
Number of subjects: 22
Study 24236810 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer modeling intervention
Number of subjects: 49
Study 24236810 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 21331628 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional beverage rich in vitamins C and E plus Lippia citriodora extract (PLX) containing 20 mg/100 ml verbascoside
Number of subjects: 10
Study 21331628 — intervention group
Group type: COMPARATOR
Intervention: Functional beverage rich in vitamins C and E (placebo)
Number of subjects: 10
Study 21331628 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional beverage rich in vitamins C and E plus Lippia citriodora extract (PLX)
Number of subjects: 10
Study 19726396 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-based chemotherapy regimens (dose‐dense taxane, dose‐standard taxane, or dose‐standard without taxane)
Number of subjects: 196
Study 17056201 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg by mouth twice per day for 2 weeks before and during CRT
Number of subjects: 31
Study 17056201 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib administration before CRT
Number of subjects: 31
Study 15163253 — intervention group
Group type: EXPERIMENTAL
Intervention: Beaded extended-release carbamazepine capsules (ERC-CBZ; SPD417) 200-1600 mg/day, mean dose 938 mg/day
Number of subjects: 92
Study 11171831 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 80
Study 11171831 — intervention group
Group type: COMPARATOR
Intervention: Ligation
Number of subjects: 80
Study 9877150 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate ingestion
Number of subjects: 30
Study 9877150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8027144 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium heparin
Number of subjects: 132
Study 8027144 — intervention group
Group type: COMPARATOR
Intervention: A‐V Impulse System (intermittent plantar pump)
Number of subjects: 132
Study 2644898 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Gastrectomy (TG)
Number of subjects: 169
Study 2644898 — intervention group
Group type: COMPARATOR
Intervention: Subtotal Gastrectomy (SG)
Number of subjects: 169
Study 182445 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitosterol
Number of subjects: 14
Study 182445 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitosterol + lipid lowering diet
Number of subjects: 14
Study 31112561 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-squat (HS) exercise
Number of subjects: 18
Study 31112561 — intervention group
Group type: COMPARATOR
Intervention: Cycle ergometer exercise
Number of subjects: 18
Study 28642125 — intervention group
Group type: EXPERIMENTAL
Intervention: VIM-only stimulation for 3 months
Number of subjects: 12
Study 28642125 — intervention group
Group type: COMPARATOR
Intervention: VO-only stimulation for 3 months
Number of subjects: 12
Study 28642125 — intervention group
Group type: EXPERIMENTAL
Intervention: Both leads activated after initial 3 months
Number of subjects: 12
Study 25411413 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dabrafenib and trametinib therapy (CombiDT) at standard dose (150/2)
Number of subjects: 201
Study 23392000 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized CDKN2A and MC1R genotyping results in the context of a genetic counseling session
Number of subjects: 73
Study 23392000 — intervention group
Group type: COMPARATOR
Intervention: Standard practice of not being offered counseling or disclosure of genotyping results
Number of subjects: 73
Study 21698100 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (10-15 mg per kg)
Number of subjects: 352
Study 21698100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study 19490462 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine 0.15 mg/kg i.v.
Number of subjects: 60
Study 19490462 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine 0.15 mg/kg + midazolam 0.01 mg/kg i.v.
Number of subjects: 60
Study 19490462 — intervention group
Group type: COMPARATOR
Intervention: saline control
Number of subjects: 60
Study 16338907 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise (1 h of cycling at 70% peak O2 uptake)
Number of subjects: 13
Study 16338907 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (8 x 5 maximal leg extensions)
Number of subjects: 13
Study 14718319 — intervention group
Group type: EXPERIMENTAL
Intervention: High amount/vigorous intensity (20 miles jogging/week at 65%-80% peak oxygen consumption)
Number of subjects: 182
Study 14718319 — intervention group
Group type: EXPERIMENTAL
Intervention: Low amount/vigorous intensity (12 miles jogging/week at 65%-80% peak oxygen consumption)
Number of subjects: 182
Study 14718319 — intervention group
Group type: EXPERIMENTAL
Intervention: Low amount/moderate intensity (12 miles walking/week at 40%-55% peak oxygen consumption)
Number of subjects: 182
Study 14718319 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 182
Study 11392343 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (2.5 mg/kg per day for 1 week, then 5.0 mg/kg per day for 3 weeks)
Number of subjects: 39
Study 11392343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 9251847 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms vaccine
Number of subjects: 30
Study 9251847 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms vaccine
Number of subjects: 30
Study 9251847 — intervention group
Group type: COMPARATOR
Intervention: Alum placebo
Number of subjects: 30
Study 11767317 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-oxygenation with 8 litre min-1 oxygen through a plastic facemask for 3 min
Number of subjects: 60
Study 11767317 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pre-oxygenation)
Number of subjects: 60
Study 2422927 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin intravenous drip (250 micrograms/h) for 4 hours, started at the beginning of operation
Number of subjects: 20
Study 2422927 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 20
Study 29411251 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention group (IG)
Number of subjects: 180
Study 29411251 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 180
Study 27444119 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet alone
Number of subjects: 60
Study 27444119 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise
Number of subjects: 60
Study 27444119 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and drug treatment
Number of subjects: 60
Study 27444119 — intervention group
Group type: COMPARATOR
Intervention: All interventions combined
Number of subjects: 60
Study 24477028 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 522
Study 24477028 — intervention group
Group type: COMPARATOR
Intervention: Non-pioglitazone
Number of subjects: 522
Study 22625878 — intervention group
Group type: COMPARATOR
Intervention: Nutritional education intervention for caregivers, conducted by nurses with 4 home visits over 6 months.
Number of subjects: 200
Study 20542419 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% benzocaine gel (B10)
Number of subjects: 30
Study 20542419 — intervention group
Group type: EXPERIMENTAL
Intervention: liposome‐encapsulated 10% benzocaine (LB10)
Number of subjects: 30
Study 20542419 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% benzocaine gel (B20)
Number of subjects: 30
Study 18395396 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based evidence training by Lady Health Workers (LHWs) using new risk communication tools.
Number of subjects: 0
Study 18395396 — intervention group
Group type: COMPARATOR
Intervention: Standard procedures used by Lady Health Workers (LHWs) in the control group.
Number of subjects: 0
Study 15538593 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 40
Study 15538593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14571352 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK‐4 (N = 8)
Number of subjects: 24
Study 14571352 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 8)
Number of subjects: 24
Study 12569689 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEGF ointments of 10 micrograms/g
Number of subjects: 120
Study 12569689 — intervention group
Group type: COMPARATOR
Intervention: Control (self-corresponding wounds of the same degree)
Number of subjects: 120
Study 9713225 — intervention group
Group type: COMPARATOR
Intervention: Laser therapy alone
Number of subjects: 26
Study 9713225 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser followed by brachytherapy
Number of subjects: 26
Study 8151900 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy plus continuing medical care (n = 328)
Number of subjects: 659
Study 8151900 — intervention group
Group type: COMPARATOR
Intervention: Medical care alone (n = 331)
Number of subjects: 659
Study 3348613 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefoperazone (2 g) and sulbactam (1 g)
Number of subjects: 6
Study 3348613 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal cefoperazone (2 g) and sulbactam (1 g)
Number of subjects: 6
Study 3348613 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dosing
Number of subjects: 6
Study 31484660 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO (500 mg orally) plus aspirin (325 mg)
Number of subjects: 104
Study 31484660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 27748986 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model for cesarean delivery based on maternal characteristics
Number of subjects: 1302
Study 27748986 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced maternal age, shorter maternal height, greater gestational age, perception of labor lasting more than 24 hours, mild or moderate contractions, less cervical dilation, and higher fetal station at time of hospital admission
Number of subjects: 1302
Study 25288189 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 15
Study 25288189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 23219623 — intervention group
Group type: EXPERIMENTAL
Intervention: RHA press‐fit cobalt‐chromium cup
Number of subjects: 71
Study 23219623 — intervention group
Group type: COMPARATOR
Intervention: THA with a threaded titanium cup and polyethylene‐metal‐inlay insert
Number of subjects: 71
Study 21788757 — intervention group
Group type: EXPERIMENTAL
Intervention: zinc-ORS
Number of subjects: 500
Study 21788757 — intervention group
Group type: COMPARATOR
Intervention: ORS
Number of subjects: 500
Study 19512972 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 57
Study 19512972 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 57
Study 16458629 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (conjugated estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg)
Number of subjects: 71
Study 16458629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 14754707 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine plus naproxen
Number of subjects: 120
Study 14754707 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine only
Number of subjects: 120
Study 14754707 — intervention group
Group type: COMPARATOR
Intervention: Naproxen only
Number of subjects: 120
Study 14754707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 11776671 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory laparoscopic cholecystectomy (AM)
Number of subjects: 86
Study 11776671 — intervention group
Group type: COMPARATOR
Intervention: Overnight stay laparoscopic cholecystectomy (OS)
Number of subjects: 86
Study 11776671 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AM and OS)
Number of subjects: 86
Study 9256142 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075% capsaicin cream applied to the painful site four times daily for 8 weeks
Number of subjects: 99
Study 9256142 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied to the painful site four times daily for 8 weeks
Number of subjects: 99
Study 9256142 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin cream
Number of subjects: 99
Study 9256142 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 99
Study 8509640 — intervention group
Group type: COMPARATOR
Intervention: Recombinant IFN alpha‐2b alone (5 MU s.c. thrice weekly for 5 months)
Number of subjects: 37
Study 8509640 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IFN alpha‐2b and recombinant IL‐2 (3 MU IFN alpha‐2b s.c. thrice weekly for 5 months, with IL-2 added starting at month 2)
Number of subjects: 37
Study 31340972 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline data model
Number of subjects: 618
Study 31340972 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline/6-week data model
Number of subjects: 618
Study 27888093 — intervention group
Group type: EXPERIMENTAL
Intervention: rATG/Daclizumab
Number of subjects: 200
Study 27888093 — intervention group
Group type: COMPARATOR
Intervention: rATG/Alemtuzumab
Number of subjects: 200
Study 26790205 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-layer embedding group (multifidus muscle layer)
Number of subjects: 90
Study 26790205 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-layer embedding group (semispinalis capitis muscle layer)
Number of subjects: 90
Study 26790205 — intervention group
Group type: COMPARATOR
Intervention: Shallow-layer embedding group (subcutaneous layer)
Number of subjects: 90
Study 23636088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided intra-articular injection through midmedial portal
Number of subjects: 120
Study 23636088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided intra-articular injection through midlateral portal
Number of subjects: 120
Study 23636088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided intra-articular injection through superolateral portal
Number of subjects: 120
Study 22117660 — intervention group
Group type: EXPERIMENTAL
Intervention: FRESH START intervention (tailored mailed print materials promoting fruit and vegetable consumption, reduced total and saturated fat intake, and/or increased exercise)
Number of subjects: 543
Study 22117660 — intervention group
Group type: COMPARATOR
Intervention: Standardized mailed materials (control group)
Number of subjects: 543
Study 18561010 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 240
Study 18561010 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 240
Study 16855169 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg, twice/weekly) and Infliximab (3 mg/kg on 0, 2, 6, and every 8 weeks thereafter)
Number of subjects: 30
Study 16855169 — intervention group
Group type: COMPARATOR
Intervention: Control group (stable therapy with prednisone and MTX without anti-TNF-alpha therapy)
Number of subjects: 30
Study 12623939 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg once daily
Number of subjects: 6311
Study 12623939 — intervention group
Group type: COMPARATOR
Intervention: Co‐amilozide (25 mg hydrochlorothiazide and 2.5 mg amiloride) daily
Number of subjects: 6311
Study 11180916 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1alpha hydroxyvitamin D3, 0.75 microg/day)
Number of subjects: 92
Study 11180916 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (menatetrenone, 45 mg/day)
Number of subjects: 92
Study 11180916 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 plus Vitamin K2
Number of subjects: 92
Study 11180916 — intervention group
Group type: COMPARATOR
Intervention: Calcium (calcium lactate, 2 g/day)
Number of subjects: 92
Study 9084066 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 0
Study 9084066 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 0
Study 9084066 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 8451526 — intervention group
Group type: EXPERIMENTAL
Intervention: STATIC
Number of subjects: 20
Study 8451526 — intervention group
Group type: COMPARATOR
Intervention: BALLISTIC
Number of subjects: 20
Study 8451526 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups
Number of subjects: 20
Study 3612353 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical insertion
Number of subjects: 102
Study 3612353 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous insertion
Number of subjects: 102
Study 3612353 — intervention group
Group type: COMPARATOR
Intervention: Both techniques (surgical and percutaneous)
Number of subjects: 102
Study 3612353 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of circulatory support
Number of subjects: 102
Study 3612353 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular complications
Number of subjects: 102
Study 3612353 — intervention group
Group type: EXPERIMENTAL
Intervention: Deaths related to circulatory assistance (percutaneous group)
Number of subjects: 102
Study 31820012 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-blind peer review
Number of subjects: 0
Study 31820012 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind peer review
Number of subjects: 0
Study 29863955 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus bevacizumab plus chemotherapy (ABCP)
Number of subjects: 692
Study 29863955 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus carboplatin plus paclitaxel (BCP)
Number of subjects: 692
Study 27646624 — intervention group
Group type: EXPERIMENTAL
Intervention: Saebo‐Flex™ device
Number of subjects: 9